Caregivers can find more information on how to communicate with their loved ones and others involved in the patient's care at www.caregiveraction.org.
About Alzheimer's DiseaseAlzheimer's disease is a progressive, neurodegenerative disorder characterized by problems with memory, thinking, and behavior that eventually become severe enough to affect work, lifelong hobbies, and social life. Every 68 seconds, someone in the United States develops Alzheimer's disease. The disease is the sixth leading cause of death in the United States. Alzheimer's-associated healthcare costs are also projected to increase from $200 billion in 2012 to $1.1 trillion by 2050.
About the Caregiver SurveyGfK Roper Public Affairs & Corporate Communications conducted the online study on behalf of Caregiver Action Network (CAN) and Forest Laboratories, Inc. The survey was conducted among 674 Alzheimer's disease (AD) caregivers between March 28 and April 25, 2011, including oversamples to reach 100 African-American and 100 Hispanic AD caregivers in the total sample. The results are weighted by age, race, and education to reflect the population of Alzheimer's disease caregivers.
About Caregiver Action NetworkThe Caregiver Action Network is the nation's leading family caregiver organization working to improve the quality of life for the more than 65 million Americans who care for loved ones with chronic conditions, disabilities, disease, or the frailties of old age. CAN serves a broad spectrum of family caregivers ranging from the parents of children with special needs, to the families and friends of wounded soldiers, from a young couple dealing with a diagnosis of MS, to adult children caring for parents with Alzheimer's disease. CAN (formerly the National Family Caregivers Association) is a non-profit organization providing education, peer support, and resources to family caregivers across the country free of charge. To learn more, visit www.caregiveraction.org.About Forest Laboratories, Inc.Forest Laboratories' (NYSE: FRX) long-standing global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine. The Company's pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com. Contact: Danielle Al-HamdouniFleishman-Hillard(212) 453-2341 Danielle.AlHamdouni@fleishman.com